BioCryst Pharmaceuticals (BCRX) 3.85 -0.12

BioCryst Pharmaceuticals, Inc.
(BCRX) 3.85 -0.12

Last Trade:	3.84	Day Range:	3.84 - 3.97
Trade Time:	08:02PM	52wk Range:	2.28 - 4.49
Prev. Close:	3.96	Market Cap:	173.62M
Open:	3.91	Div Yield:	0
Volume:	144906	PE:
EPS:	-0.76

The Latest On BCRX

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12 1:19pm

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12 1:18pm

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12 11:20am

UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico 1/23/12 11:00am

Benzinga's Microcap Movers for Thursday January 12, 2012 1/12/12 6:41pm

Oink Oink: Profit From The Return Of Swine Flu 1/12/12 1:40pm

UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX4208 1/12/12 11:21am

Bank of America Comments on BCRX Phase-3 Data 1/12/12 11:18am

From Earlier: BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout 1/9/12 6:54am

BioCryst Data Boosts Price Action 11/8/11 2:52pm

BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting 10/24/11 9:00am

Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue 10/24/11 7:46am

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12

UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico 1/23/12

Benzinga's Microcap Movers for Thursday January 12, 2012 1/12/12

Oink Oink: Profit From The Return Of Swine Flu 1/12/12

UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX4208 1/12/12

Bank of America Comments on BCRX Phase-3 Data 1/12/12

From Earlier: BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout 1/9/12

BioCryst Data Boosts Price Action 11/8/11

BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting 10/24/11

Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue 10/24/11

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12

Benzinga's Microcap Movers for Thursday January 12, 2012 1/12/12

Oink Oink: Profit From The Return Of Swine Flu 1/12/12

UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX4208 1/12/12

Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue 10/24/11

Shorts Left to Scramble as BioCryst Announces Positive Mid-Stage Trial Results 10/5/11

Top Percentage Gainers and Losers as of 2pm 06/13/11 6/13/11

Top Percentage Gainers and Losers as of 12pm 06/13/11 6/13/11

BioCryst Initiates a Phase 2b Study of BCX4208 (BCRX) 12/22/10

Biotech and Pharma Stocks: High Volume Traders; (OTCBB: UVFT), (NASDAQ:AMGN), (OTCBB: GNTA), (NASDAQ:BCRX) 12/15/10

UPDATE: Bank of America Meets with BioCryst Pharma Management on BCX4208 1/12/12

Bank of America Comments on BCRX Phase-3 Data 1/12/12

Rodman & Renshaw Reiterates Outperform Rating on BioCryst Pharmaceuticals 10/5/11

Rodman & Renshaw Provides Color on BioCryst Pharmaceuticals 7/5/11

Rodman & Renshaw Reiterate Market Outperform and PT of $7 on BioCryst Pharmaceuticals 6/13/11

BioCryst Upgraded To Outperform 9/29/10

BofA/Merrill Downgrades BCRX To Underperform 9/23/10

Trade BCRX
NOW!

Partner Headlines

5 Under-$10 Stocks Set to Soar 12/29/11

Zacks #5 Rank Additions for Friday - Tale of the Tape 11/4/11

BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) 11/3/11

Biocryst's Gout Drug Fails to Impress 10/5/11

Dendreon's Blowup Spreads Across Biotech 8/4/11

Biotech Calendar: Key Dates for September 9/1/10

Demand for BioCryst Flu Drug Still Low: BioBuzz 3/30/10

BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

Press Releases

BioCryst to Announce Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012 2/6/12 Business Wire Story

Nancy Hutson Appointed to BioCryst's Board of Directors 1/19/12 Business Wire Story

BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout 1/8/12 Business Wire Story

BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting 11/8/11 Business Wire Story

BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results 11/2/11 Business Wire Story

BioCryst Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 2, 2011 8/30/11 Business Wire Story

BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone 8/30/11 Business Wire Story

BioCryst to Present at Three Upcoming Investor Conferences 8/30/11 Business Wire Story

BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results 8/30/11 Business Wire Story

BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting 8/30/11 Business Wire Story

Biocryst Pharmaceuticals Announces Changes to Its Board of Directors 8/30/11 Business Wire Story

BioCryst To Present New Peramivir Data at the 51st Annual ICAAC Meeting 8/30/11 Business Wire Story

Get the latest BCRX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for BioCryst Pharmaceuticals, Inc. stock price.

BioCryst Pharmaceuticals, Inc. by YCharts